|
Delaware
|
| |
2834
|
| |
81-1065054
|
|
|
(State or other jurisdiction of
incorporation or organization) |
| |
(Primary Standard Industrial
Classification Code Number) |
| |
(I.R.S. Employer
Identification No.) |
|
|
Michael Bison
Finnbarr Murphy Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 (617) 570-1000 |
| |
Thomas A. Fitzgerald
Chief Financial Officer TransCode Therapeutics, Inc. 6 Liberty Square, #2382 Boston, MA 02109 (857) 837-3099 |
| |
Stephen Older
Rakesh Gopalan David S. Wolpa McGuireWoods LLP 1251 Avenue of the Americas, 20th Fl. New York, NY 10020 (212) 548-2122 |
|
| Large accelerated filer | | | ☐ | | |
Accelerated filer
|
| | ☐ | |
|
Non-accelerated filer
|
| | ☒ | | |
Smaller reporting company
|
| | ☒ | |
| | | | | | |
Emerging growth company
|
| | ☒ | |
| PRELIMINARY PROSPECTUS | | |
SUBJECT TO COMPLETION
|
| |
DATED AUGUST 29, 2023
|
|
| | |
Per Share
|
| |
Per Pre-Funded
Warrant |
| |
Total
|
| |||||||||
Public offering price
|
| | | $ | | | | | $ | | | | | $ | | | |||
Underwriting discounts and commissions(1)
|
| | | $ | | | | | $ | | | | | $ | | | |||
Proceeds to us, before expenses
|
| | | $ | | | | | $ | | | | | $ | | | |
| | | | | i | | | |
| | | | | ii | | | |
| | | | | iii | | | |
| | | | | 1 | | | |
| | | | | 14 | | | |
| | | | | 17 | | | |
| | | | | 19 | | | |
| | | | | 29 | | | |
| | | | | 31 | | | |
| | | | | 32 | | | |
| | | | | 33 | | | |
| CAPITALIZATION | | | | | 34 | | |
| | | | | 36 | | | |
| | | | | 38 | | | |
| | | | | 44 | | | |
| | | | | 50 | | | |
| | | | | 56 | | | |
| | | | | 56 | | |
| | |
Six Months Ended June 30,
|
| |
Years Ended December 31,
|
| ||||||||||||||||||
| | |
2023
|
| |
2022
|
| |
2022
|
| |
2021
|
| ||||||||||||
| | |
Unaudited
|
| | | | | | | | | | | | | |||||||||
Statement of Operations Data | | | | | | ||||||||||||||||||||
Operating expenses | | | | | | | | | | | | | | | | | | | | | | | | | |
Research and development
|
| | | $ | 5,557,260 | | | | | $ | 4,501,604 | | | | | $ | 10,232,366 | | | | | $ | 2,753,966 | | |
General and administrative
|
| | | | 4,474,688 | | | | | | 3,683,191 | | | | | | 8,433,448 | | | | | | 3,397,169 | | |
Total operating expenses
|
| | | | 10,031,948 | | | | | | 8,184,795 | | | | | | 18,665,814 | | | | | | 6,151,135 | | |
Operating loss
|
| | | | (10,031,948) | | | | | | (8,184,795) | | | | | | (18,665,814) | | | | | | (6,151,135) | | |
Other income (expense) | | | | | | | | | | | | | | | | | | | | | | | | | |
Change in fair value of derivative liabilities
|
| | | | — | | | | | | — | | | | | | — | | | | | | (867,000) | | |
Change in fair value of warranty liability
|
| | | | — | | | | | | — | | | | | | — | | | | | | (6,109) | | |
Grant income
|
| | | | 868,345 | | | | | | 41,720 | | | | | | 1,080,436 | | | | | | 278,333 | | |
Loss on sale of equipment
|
| | | | — | | | | | | — | | | | | | — | | | | | | (3,082) | | |
Interest expense
|
| | | | — | | | | | | — | | | | | | — | | | | | | (95,070) | | |
Interest income
|
| | | | 5,017 | | | | | | 1,773 | | | | | | 20,410 | | | | | | 664 | | |
Total other income (expense)
|
| | | | 873,362 | | | | | | 43,493 | | | | | | 1,100,846 | | | | | | (692,264) | | |
Loss before income taxes
|
| | | | (9,158,586) | | | | | | (8,141,302) | | | | | | (17,564,968) | | | | | | (6,843,399) | | |
Income tax expense (benefit)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Net loss
|
| | | $ | (9,158,586) | | | | | $ | (8,141,302) | | | | | $ | (17,564,968) | | | | | $ | (6,843,399) | | |
Basic and diluted loss per common share(1)
|
| | | $ | (8.97) | | | | | $ | (12.55) | | | | | $ | (27.07) | | | | | $ | (16.24) | | |
Weighted average number of common shares outstanding, basic and diluted(1)
|
| | | | 1,020,644 | | | | | | 648,862 | | | | | | 648,861 | | | | | | 421,294 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | |
December 31,
|
| |||||||||
| | |
June 30, 2023
|
| |
2022
|
| |
2021
|
| |||||||||
| | |
Unaudited
|
| | | | | | | | | | | | | |||
Balance Sheet Data | | | | | | | | | | | | | | | | | | | |
Cash | | | | $ | 3,572,475 | | | | | $ | 4,968,418 | | | | | $ | 20,825,860 | | |
Current assets
|
| | | | 4,892,937 | | | | | | 7,379,405 | | | | | | 22,732,175 | | |
Total assets
|
| | | | 5,881,545 | | | | | | 7,587,986 | | | | | | 22,938,443 | | |
Current liabilities
|
| | | | 3,523,430 | | | | | | 4,347,290 | | | | | | 2,534,097 | | |
Total liabilities
|
| | | | 3,789,082 | | | | | | 4,347,290 | | | | | | 2,534,097 | | |
Total stockholders’ equity
|
| | | | 2,092,463 | | | | | | 3,240,696 | | | | | | 20,404,346 | | |
| | | | | | | | | | | | | | | | | | | |
| | |
June 30, 2023
|
| |||||||||
| | |
(unaudited)
|
| |||||||||
| | |
Actual
|
| |
As Adjusted
|
| ||||||
Cash
|
| | | $ | 3,572,475 | | | | | $ | | | |
Stockholders’ equity | | | | | | | | | | | | | |
Preferred stock – $0.0001 par value; 10,000,000 shares authorized actual and as adjusted; no shares issued or outstanding actual or as adjusted
|
| | | | — | | | | | | — | | |
Common stock – $0.0001 par value; 290,000,000 shares authorized; 1,950,674 shares issued and outstanding actual; shares issued and outstanding as adjusted
|
| | | $ | 195 | | | | | $ | | | |
Additional paid-in capital
|
| | | | 39,121,104 | | | | | | | | |
Accumulated deficit
|
| | | | (37,028,836) | | | | | | | | |
Total stockholders’ equity
|
| | | $ | 2,092,463 | | | | | $ | | | |
Total capitalization
|
| | | $ | 2,092,463 | | | | | $ | | | |
| | | | | | | | | | | | | |
|
Assumed public offering price per share
|
| | | | | | | | | $ | | | |
|
Net tangible book value per share at June 30, 2023
|
| | | $ | 1.03 | | | | | | | | |
|
Increase in book value per share attributable to new investors
|
| | | $ | | | | | | | | | |
|
As adjusted net tangible book value per share after this offering
|
| | | | | | | | | $ | | | |
|
Dilution per share to new investors
|
| | | | | | | | | $ | | | |
| | | | | | | | | | | | | | |
Description
|
| |
Number
of Shares |
| |
Exercise Price
Per Share |
| ||||||
IPO Underwriter Warrants
|
| | | | 15,625 | | | | | $ | 100.00 | | |
February 2023 Placement Agent Warrants
|
| | | | 9,962 | | | | | | 13.18 | | |
Consultant Warrants
|
| | | | 6,250 | | | | | | 10.00 | | |
Series A-1 Warrants
|
| | | | 2,000,000 | | | | | | 3.25 | | |
Series A-2 Warrants
|
| | | | 2,000,000 | | | | | | 3.25 | | |
June 2023 Placement Agent Warrants
|
| | | | 140,000 | | | | | | 4.38 | | |
June 2023 Pre-funded Warrants
|
| | | | 950,000 | | | | | | 0.01 | | |
| | | | | | | | | | | | | |
Underwriter
|
| |
Number of
Shares |
| |
Number of
Pre-Funded Warrants |
|
ThinkEquity
|
| | | | | | |
Total
|
| | | | | | |
| | | | | | | |
| | |
Per Share
|
| |
Per Pre-Funded
Warrant |
| |
With No
Over-Allotment |
| |
With Full
Over-Allotment |
| ||||||||||||
Public offering price
|
| | | $ | | | | | $ | | | | | $ | | | | | $ | | | ||||
Underwriting discount (7.5%)
|
| | | $ | | | | | $ | | | | | $ | | | | | $ | | | ||||
Proceeds, before expenses, to us
|
| | | $ | | | | | $ | | | | | $ | | | | | $ | | | ||||
Non-accountable expense allowance (1%)
|
| | | $ | | | | | $ | | | | | $ | | | | | $ | | | | |||
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | |
Amount paid or
to be paid |
| |||
SEC registration fee
|
| | | $ | 1,346.51 | | |
FINRA filing fee
|
| | | | | | |
Printing and mailing
|
| | | | | | |
Legal fees and expenses
|
| | | | | | |
Accounting fees and expenses
|
| | | | | | |
Miscellaneous
|
| | | | | | |
Total
|
| | | $ | 495,000 | | |
| | | | | | | |
| | | |||
|
Exhibit
number |
| |
Description
|
|
| 1.1** | | | Form of Underwriting Agreement. | |
| 3.1 | | | | |
| 3.2 | | | | |
| 3.3 | | | | |
| 4.1 | | | | |
| 4.2** | | | Form of Pre-funded Warrant. | |
| 4.3** | | | Form of Underwriter’s Warrant. | |
| 4.4 | | | | |
| 4.5 | | | | |
| 4.6 | | | | |
| 4.7 | | | | |
| 4.8 | | | | |
| 5.1** | | | Opinion of Goodwin Procter LLP. | |
| 10.1# | | | | |
| 10.2# | | | |
| | | |||
|
Exhibit
number |
| |
Description
|
|
| 10.3# | | | | |
| 10.4# | | | | |
| 10.5# | | | | |
| 10.6 | | | | |
| 10.7# | | | | |
| 10.8# | | | | |
| 10.9# | | | | |
| 10.10# | | | | |
| 10.11# | | | | |
| 10.12# | | | | |
| 10.13 | | | | |
| 10.14 | | | | |
| 10.15 | | | | |
| 21.1* | | | List of Subsidiaries of the Registrant. | |
| 23.1* | | | Consent of Withum Smith+Brown, PC, independent registered public accounting firm. | |
| 23.2** | | | Consent of Goodwin Procter LLP (included in Exhibit 5.1). | |
| 24.1* | | | Power of Attorney (included on signature page). | |
| 107* | | | Filing Fee Table. | |
| | | ||||||
|
NAME
|
| |
TITLE
|
| |
DATE
|
|
|
/s/ Robert Michael Dudley
Robert Michael Dudley
|
| |
Director and Chief Executive Officer
(Principal Executive Officer) |
| |
August 29, 2023
|
|
|
/s/ Thomas A. Fitzgerald
Thomas A. Fitzgerald, MBA
|
| |
Director and Chief Financial Officer (Principal Financial and Accounting Officer)
|
| |
August 29, 2023
|
|
|
/s/ Philippe P. Calais, PhD
Philippe P. Calais, PhD
|
| |
Director
|
| |
August 29, 2023
|
|
|
/s/ Erik Manting, PhD
Erik Manting, PhD
|
| |
Director
|
| |
August 29, 2023
|
|
|
/s/ Magda Marquet, PhD
Magda Marquet, PhD
|
| |
Director
|
| |
August 29, 2023
|
|
| | | | | | | | |
Exhibit 21.1
List of Subsidiaries
None
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement on Form S-1, of our report dated March 31, 2023, which includes an explanatory paragraph relating to Transcode Therapeutics, Inc.’s ability to continue as a going concern, relating to the financial statements of Transcode Therapeutics, Inc., which is incorporated by reference in that Prospectus. We also consent to the reference to us under the caption “Experts” in the Prospectus.
/s/ WithumSmith+Brown, PC
East Brunswick, New Jersey
August 29, 2023
Exhibit 107
Calculation of Filing Fee Tables
Form S-1
(Form Type)
TransCode Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
Security Type |
Security Class |
Fee Calculation or Carry Forward Rule |
Amount Registered |
Proposed Maximum Offering Price Per Unit |
Maximum Aggregate |
Fee |
Amount of Registration Fee | |||||||
Fees to be Paid |
Equity |
Common Stock, $0.0001 par value per share(7) |
457(o) | ꟷ | ꟷ | $11,500,000 | 0.0001102 | $1,267.30 | ||||||
Fees to be Paid |
Equity |
Pre-funded warrants to purchase Common Stock, $0.0001 par value per share(4)(7)(8) |
457(g) | ꟷ | ꟷ | ꟷ | ꟷ | ꟷ | ||||||
Fees to be Paid |
Equity |
Common Stock, $0.0001 par value per share underlying the Pre-funded warrants(5)(7)(8) |
Other | ꟷ | ꟷ | ꟷ | ꟷ | ꟷ | ||||||
Fees to be Paid |
Equity |
Underwriter’s Warrants to Purchase Common Stock, $0.0001 par value per share(3)(4) |
457(g) | ꟷ | ꟷ | ꟷ | ꟷ | ꟷ | ||||||
Fees to be Paid |
Equity |
Common Stock, $0.0001 par value per share underlying the Underwriter’s Warrants(5)(6) |
457(o) | ꟷ | ꟷ | $718,750 | 0.0001102 | $79.21 | ||||||
Total Offering Amounts | $12,218,750 | $1,346.51 | ||||||||||||
Total Fees Previously Paid | $0 | |||||||||||||
Net Fee Due | $1,346.51 |
(1) | Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the “Securities Act”). |
(2) | Includes the aggregate offering price of additional shares that the underwriter has the option to purchase pursuant to its over-allotment option. |
(3) | We have agreed to issue to the underwriter warrants to purchase the number of shares of our common stock (the “Underwriter’s Warrants”) in the aggregate equal to five percent (5%) of the shares of our common stock to be issued and sold in this offering, including upon exercise the option to purchase additional securities. |
(4) | No registration fee is required pursuant to Rule 457(g) under the Securities Act. |
(5) | In addition to the common stock set forth in this table, pursuant to Rule 416 under the Securities Act, this registration statement also registers such indeterminate number of common stock as may become issuable upon exercise of the Underwriter’s Warrants and pre-funded warrants. |
(6) | The Underwriter’s Warrants are exercisable for a price per share equal to 125% of the public offering price in this offering. As estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(g), the proposed maximum aggregate offering price of the Representative’s Warrants is $718,7500, which is equal to 125% of $575,000 (5% of the proposed maximum aggregate offering price of $11,500,000). |
(7) | The proposed maximum aggregate offering price of the common stock proposed to be sold in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any pre-funded warrants offered and sold in the offering, and as such the proposed maximum offering price of the common stock and pre-funded warrants (including the common stock issuable upon exercise of the pre-funded warrants) if any, is $11,500,000. |
(8) | The registrant may issue pre-funded warrants to purchase common stock in the offering. The purchase price of each pre-funded warrant will equal the price per share at which shares of common stock are being sold to the public in this offering, minus $0.01, which constitutes the pre-funded portion of the exercise price, and the remaining unpaid exercise price of the pre-funded warrant will equal $0.01 per share (subject to adjustment as provided for therein). |